FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
CJC-1295 No DAC 10mg research peptide vial
Growth & Longevity

CJC-1295 No DAC

Mod GRF (1-29)

A GHRH analog (no DAC) studied in growth-hormone pulsatility research.

$110

In stock · ships in 1–2 business days

  • ✓ 99.798% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
GHRHGH research

Research Summary

CJC-1295 without DAC (Mod GRF 1-29) is a GHRH analog studied in preclinical research for its short-acting stimulation of growth-hormone release and pulsatile secretion models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

CJC-1295 No DAC: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is CJC-1295 No DAC?

CJC-1295 No DAC, also called Mod GRF (1-29), is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). Its backbone is GHRH(1-29)-NH2, the shortest fragment of the natural 44-residue hormone that retains its full biological activity [1]. Compared with that native fragment, four positions are changed: alanine at position 2 is replaced by its D-isomer, asparagine 8 by glutamine, glycine 15 by alanine, and methionine 27 by leucine [2] [3].

The developers of CJC-1295 described their compound as a tetrasubstituted form of hGRF(1-29) [4]. The "No DAC" peptide is that tetrasubstituted sequence on its own, without the chemical linker that defines the original CJC-1295. Anti-doping chemists refer to this peptide as "modified GRF 1-29" [5].

The unmodified GHRH(1-29)-NH2 sequence is available separately as sermorelin, and the long-acting form as CJC-1295 with DAC. Browse all growth-axis research compounds.

CJC-1295 No DAC molecular identity
SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Length29 amino acids, C-terminal amide
Substitutions vs hGRF(1-29)-NH2D-Ala2, Gln8, Ala15, Leu27
Molecular formulaC152H252N44O42
Molecular weight3367.9 g/mol
PubChem CID56841945
Other namesMod GRF (1-29), modified GRF 1-29, tetrasubstituted hGRF(1-29)

With DAC versus without DAC

"DAC" stands for drug affinity complex. In the 2005 paper that introduced CJC-1295, the authors added an N-epsilon-3-maleimidopropionamide derivative of lysine to the C-terminus of the tetrasubstituted hGRF(1-29). That reactive group bonds to the free thiol on cysteine 34 of serum albumin. In rats, the conjugated peptide was detected in plasma beyond 72 hours, and an immunoreactive species appeared on the serum albumin band within 15 minutes [4].

The No DAC peptide lacks this albumin-binding group. Its resistance to breakdown rests on the four amino-acid substitutions alone, so it is not expected to share the extended plasma presence reported for the DAC form. The two compounds also differ in molecular weight (3367.9 g/mol without DAC versus 3647.2 g/mol for the PubChem CJC-1295 record with the maleimide group), which mass spectrometry separates readily [2] [6]. Researchers comparing literature should check which form a study used, since most published CJC-1295 work concerns the DAC version.

Mechanisms studied

The GHRH receptor

GHRH analogs act on the GHRH receptor of pituitary somatotroph cells. The receptor belongs to family B of the G protein-coupled receptor superfamily and signals mainly through cAMP [7]. In the model described by the same research group, GHRH binding to this Gs-coupled receptor triggers growth hormone release from secretory granules and raises intracellular cAMP; cAMP-dependent phosphorylation of the transcription factor CREB then supports expression of Pit-1, which regulates the growth hormone gene [8]. GHRH also activated the MAP kinase pathway in somatotroph cells and regulated their proliferation during development [7].

Why the four substitutions

Native GHRH is broken down quickly in plasma. A 1986 study found that human plasma cleaved GHRH(1-44)-NH2 at its N-terminus to GHRH(3-44)-NH2, a product with less than one-thousandth of the original biological activity [9]. A 1989 follow-up identified the enzyme as dipeptidyl peptidase IV (DPP-IV), showed that GHRH(1-29)-NH2 is cleaved the same way, and found that a D-amino acid at position 1 or 2 prevented this cleavage. It also described secondary trypsin-like cleavage near positions 11 to 13 [10].

A 1994 study summarized two further weak points of the native sequence in water: asparagine 8 tends to rearrange to aspartate through a succinimide intermediate, and methionine 27 oxidizes, both of which reduce bioactivity. The authors also noted earlier evidence that alanine at position 15 increases receptor binding affinity [3]. The D-Ala2, Gln8, Ala15, and Leu27 changes in Mod GRF (1-29) correspond to each of these points. In a related bovine GRF series, combining a position-2 change with Ala15 improved in vivo GH-releasing activity in steers [11].

Areas of research

Pituitary cell and rodent models

In the 2005 CJC-1295 study, albumin conjugates of hGRF(1-29) derivatives showed enhanced in vitro stability against DPP-IV and stimulated GH secretion in cultured rat anterior pituitary cells. In rats, the selected compound produced a 4-fold larger growth hormone area under the curve over two hours than unmodified hGRF(1-29) [4]. These data describe the DAC form; dedicated peer-reviewed studies of the unconjugated tetrasubstituted peptide are sparse in PubMed.

Growth hormone pulsatility

Growth hormone is normally released in pulses, and how GHRH analogs affect that pattern is an active research question. In a 2006 study of the DAC form in healthy men, growth hormone secretion rose while pulse frequency and magnitude were unchanged, the increase coming mainly from higher trough levels [12]. Whether an analog without the albumin-binding group affects the pulse pattern differently has not, to our knowledge, been compared directly in a published study.

Combination research with secretagogues

GHRH analogs are often studied alongside growth hormone secretagogues, which act on a different receptor. Ipamorelin, for example, released GH in rat pituitary cells via a GHRP-like receptor rather than the GHRH receptor [13]. We also offer the CJC-1295 No DAC + Ipamorelin blend.

Analytical chemistry

Anti-doping laboratories have identified modified GRF 1-29 in seized pharmaceutical preparations, including analogs carrying an extra N-terminal glycine that standard methods could miss [5]. This is one reason independent identity testing by mass spectrometry matters for this compound.

Open research questions

  • Plasma stability and receptor potency of the unconjugated tetrasubstituted peptide, measured directly and published in peer-reviewed form.
  • How results from DAC studies translate, if at all, to the No DAC peptide.

State of the human evidence

Published human studies under the CJC-1295 name concern the albumin-binding DAC form [12]. We found no peer-reviewed controlled human trials of the No DAC peptide in PubMed. A 2026 review of compounds marketed as research chemicals that act on the growth hormone axis lists CJC-1295 with and without DAC separately and groups such compounds into evidence tiers that range down to a complete absence of human studies [14]. FDA has noted that clinical data on CJC-1295 are limited [15].

Findings from cell and animal models should not be read as evidence of safety or benefit in people.

Regulatory status

Checked against primary sources on October 12, 2026.

  • Not FDA approved. No application for CJC-1295 in either form appears in FDA's Drugs@FDA database of approved drug products [16].
  • Compounding. FDA's page on bulk drug substances that may present significant safety risks (content current as of April 22, 2026) lists CJC-1295 among substances previously in category 2 whose nominations were withdrawn. FDA's note cites a possible risk of immunogenicity for certain routes of administration, complexities with peptide-related impurities and characterization, and serious adverse events including increased heart rate and a systemic vasodilatory reaction. The entry does not distinguish between the DAC and No DAC forms [15].
  • Sport. The World Anti-Doping Agency's 2026 Prohibited List names CJC-1295 as an example of a GHRH analog under section S2.2.4, within substances prohibited at all times [17].

Rejuvatide supplies CJC-1295 No DAC strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

Every Rejuvatide lot of CJC-1295 No DAC is tested by an independent laboratory for purity by HPLC and identity by mass spectrometry, and is also tested for endotoxin. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

Storage of lyophilized material

CJC-1295 No DAC ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of CJC-1295 No DAC.

99.798%HPLC purity
Lot 25091506Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

CJC-1295 No DAC FAQ

What is CJC-1295 No DAC?

It is Mod GRF (1-29), a 29-amino-acid GHRH analog with four substitutions (D-Ala2, Gln8, Ala15, Leu27) that address the enzymatic and chemical weak points of the native GHRH(1-29) sequence.

What is the difference between CJC-1295 with DAC and without DAC?

The DAC version carries an extra lysine with a maleimide group that bonds to serum albumin, which extended its plasma presence in rats beyond 72 hours. The No DAC peptide has the same 29-residue backbone without that group.

Is CJC-1295 No DAC the same as sermorelin?

No. Sermorelin is the native GHRH(1-29) amide sequence. CJC-1295 No DAC differs from it at four positions.

Is CJC-1295 FDA approved?

No. Neither form is FDA approved. FDA lists CJC-1295 among bulk substances whose compounding nominations were withdrawn, with a note on potential safety risks.

How is Rejuvatide CJC-1295 No DAC tested?

Each lot is tested by an independent laboratory for HPLC purity, mass-spec identity, and endotoxin. Certificates are published on the product page and in the COA library, matched to the lot number on the vial.

Is CJC-1295 banned in sport?

Yes. The 2026 WADA Prohibited List names CJC-1295 as a GHRH analog under S2, prohibited at all times.

Is CJC-1295 No DAC for human use?

No. Rejuvatide sells it for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. Prakash A, Goa KL. BioDrugs. 1999;12(2):139-57. PubMed 18031173
  2. PubChem. Compound CID 56841945 (tetrasubstituted GRF(1-29) amide). National Library of Medicine. Source
  3. Campbell RM, Stricker P, Miller R, et al. Peptides. 1994;15(3):489-95. PubMed 7937325
  4. Jetté L, Léger R, Thibaudeau K, et al. Endocrinology. 2005;146(7):3052-8. PubMed 15817669
  5. Gajda PM, Holm NB, Hoej LJ, et al. Drug Test Anal. 2019;11(2):350-354. PubMed 30136411
  6. PubChem. CJC-1295, Compound CID 91971820. National Library of Medicine. Source
  7. Mayo KE, Miller T, DeAlmeida V, et al. Recent Prog Horm Res. 2000;55:237-66; discussion 266-7. PubMed 11036940
  8. Mayo KE, Godfrey PA, Suhr ST, et al. Recent Prog Horm Res. 1995;50:35-73. PubMed 7740167
  9. Frohman LA, Downs TR, Williams TC, et al. J Clin Invest. 1986;78(4):906-13. PubMed 3093533
  10. Frohman LA, Downs TR, Heimer EP, et al. J Clin Invest. 1989;83(5):1533-40. PubMed 2565342
  11. Kubiak TM, Friedman AR, Martin RA, et al. J Med Chem. 1993;36(7):888-97. PubMed 8464043
  12. Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-7. PubMed 17018654
  13. Raun K, Hansen BS, Johansen NL, et al. Eur J Endocrinol. 1998;139(5):552-61. PubMed 9849822
  14. Dominikowski A, Rękoś Z, Olejarz M, et al. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
  15. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  16. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs (searched October 12, 2026). Source
  17. World Anti-Doping Agency. The 2026 Prohibited List, section S2.2.4 (official text as published in Tractatenblad 2026, no. 25). Source